Assessment of Voriconazole Penetration Into the Brain by Fluorine-Magnetic Resonance Spectroscopy
Phase 1
Completed
- Conditions
- Fungal Infection
- Registration Number
- NCT00136968
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to determine the amount of voriconazole in the brain by fluorine-magnetic resonance spectroscopy (MRS) and to compare brain levels to plasma levels.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 12
Inclusion Criteria
- Healthy male volunteers 18-55 years of age
Exclusion Criteria
- Subjects with any condition affecting drug absorption
- Subjects with a positive urine drug screen
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Assess brain levels of voriconazole in the brain using a non-evasive technique of MRS
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does fluorine-MRS quantify voriconazole brain penetration in fungal infection trials?
What are the pharmacokinetic correlations between voriconazole plasma and cerebral concentrations in NCT00136968?
Do CYP2C19 polymorphisms affect voriconazole CNS distribution in Phase 1 Pfizer trials?
How does voriconazole compare to amphotericin B in treating CNS fungal infections via drug delivery mechanisms?
What molecular targets in the blood-brain barrier influence triazole antifungal efficacy as studied in NCT00136968?